 Zoryve roflumilast cream was approved by the FDA to treat psoriasis on August 1, 2022. The phase 3 STRATUM trial met the endpoint and an NDA will be submitted to FDA for roflumilast foam to be approved for the treatment of seborrheic dermatitis. 